| |
| | ENABLEX Efficacy (Site not responding. Last check: 2007-10-19) |
 | | After this period, patients were allowed to titrate to darifenacin 15 mg if additional efficacy was required by both the patient and physician and the 7.5-mg dose was well tolerated. |
 | | Efficacy was recorded via an electronic diary during the run-in phase and during weeks 1 to 2 and 11 to 12 of the study phase. |
 | | In all fixed-dose, placebo-controlled clinical trials, the incidence of the most frequently reported adverse events for ENABLEX 7.5 mg, 15 mg, and placebo was: dry mouth (20.2%, 35.3%, 8.2%); constipation (14.8%, 21.3%, 6.2%); dyspepsia (2.7%, 8.4%, 2.6%); and abdominal pain (2.4%, 3.9%, 0.5%). |
| www.enablex.com /hcp/enablex-efficacy.jsp (348 words) |
|